{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:14:17Z","timestamp":1760235257792,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["287829"],"award-info":[{"award-number":["287829"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["197984"],"award-info":[{"award-number":["197984"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005029","name":"Helse Vest Regionalt Helsef\u00f8retak","doi-asserted-by":"publisher","award":["303484;  502027; 912062; 911626; 911747; 911582; 911778; 912226; 980058"],"award-info":[{"award-number":["303484;  502027; 912062; 911626; 911747; 911582; 911778; 912226; 980058"]}],"id":[{"id":"10.13039\/501100005029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Modulation of \u03b2-catenin signaling has attractive therapeutic potential in cancer immunotherapy. Several studies have found that \u03b2-catenin can mediate immune evasion in cancer and promote anti-inflammatory features of antigen-presenting dendritic cells. Many small molecular compounds that inhibit Wnt\/\u03b2-catenin signaling are currently in clinical development, but none have entered routine clinical use. New inhibitors of \u03b2-catenin signaling are consequently desirable. Here, we have tested, in monocyte-derived dendritic cells, the effects of two small molecular compounds, axitinib and nitazoxanide, that previously have been discovered to inhibit \u03b2-catenin signaling in colon cancer cells. Immature and lipopolysaccharide-matured dendritic cells prepared from healthy blood donor buffy coats were stimulated with 6-bromoindirubin-3\u2032-oxime (6-BIO) to boost basal \u03b2-catenin activity, and the effects of axitinib and nitazoxanide were compared with the commercial \u03b2-catenin inhibitor ICG-001. Assays, including genome-wide RNA-sequencing, indicated that neither axitinib nor nitazoxanide demonstrated considerable \u03b2-catenin inhibition. Both compounds were found to be less toxic to monocyte-derived dendritic cells than either 6-BIO or ICG-001. Axitinib stimulated several aspects of dendritic cell function, such as IL12-p70 secretion, and counteracted IL-10 secretion, according to the present study. However, neither axitinib nor nitazoxanide were found to be efficient \u03b2-catenin inhibitors in monocyte-derived dendritic cells.<\/jats:p>","DOI":"10.3390\/biomedicines9080949","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T08:16:39Z","timestamp":1627978599000},"page":"949","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of \u03b2-Catenin Inhibition of Axitinib and Nitazoxanide in Human Monocyte-Derived Dendritic Cells"],"prefix":"10.3390","volume":"9","author":[{"given":"Waqas","family":"Azeem","sequence":"first","affiliation":[{"name":"Department of Microbiology, Haukeland University Hospital, Helse Bergen, NO-5021 Bergen, Norway"},{"name":"Department of Clinical Science, University of Bergen, NO-5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragnhild Maukon","family":"Bakke","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Haukeland University Hospital, Helse Bergen, NO-5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0762-9082","authenticated-orcid":false,"given":"Benjamin","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Haukeland University Hospital, Helse Bergen, NO-5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Appel","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, NO-5021 Bergen, Norway"},{"name":"Broegelmann Research Laboratory, University of Bergen, NO-5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Margrete","family":"\u00d8yan","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, NO-5021 Bergen, Norway"},{"name":"Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Helse Bergen, NO-5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4486-2334","authenticated-orcid":false,"given":"Karl-Henning","family":"Kalland","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Haukeland University Hospital, Helse Bergen, NO-5021 Bergen, Norway"},{"name":"Department of Clinical Science, University of Bergen, NO-5021 Bergen, Norway"},{"name":"Norway Centre for Cancer Biomarkers, (CCBIO), University of Bergen, NO-5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Kypta","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"El-Sahli, S., Xie, Y., Wang, L., and Liu, S. (2019). Wnt signaling in cancer metabolism and immunity. Cancers, 11.","DOI":"10.3390\/cancers11070904"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.tcb.2018.08.005","article-title":"WNT signaling in cancer immunosurveillance","volume":"29","author":"Galluzzi","year":"2019","journal-title":"Trends Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3389\/fimmu.2019.02854","article-title":"WNT signaling in tumors: The way to evade drugs and immunity","volume":"10","author":"Nicolas","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104794","DOI":"10.1016\/j.phrs.2020.104794","article-title":"Targeting the \u03b2-catenin signaling for cancer therapy","volume":"160","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fimmu.2020.00122","article-title":"Wnt signaling cascade in dendritic cells and regulation of anti-tumor immunity","volume":"11","author":"Suryawanshi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.tips.2018.03.008","article-title":"Targeting Wnt\/beta-Catenin Signaling for Cancer Immunotherapy","volume":"39","author":"Wang","year":"2018","journal-title":"Trends Pharm. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.4049\/jimmunol.1203002","article-title":"Canonical and noncanonical Wnt proteins program dendritic cell responses for tolerance","volume":"190","author":"Oderup","year":"2013","journal-title":"J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1126\/science.1188510","article-title":"Activation of -catenin in dendritic cells regulates immunity versus tolerance in the intestine","volume":"329","author":"Manicassamy","year":"2010","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fimmu.2020.00438","article-title":"Dual Pro- and Anti-Inflammatory Features of Monocyte-Derived Dendritic Cells","volume":"11","author":"Azeem","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Blagodatski, A., Klimenko, A., Jia, L., and Katanaev, V.L. (2020). Small molecule wnt pathway modulators from natural sources: History, state of the art and perspectives. Cells, 9.","DOI":"10.3390\/cells9030589"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.tibs.2018.06.003","article-title":"Is \u03b2-Catenin a druggable target for cancer therapy?","volume":"43","author":"Cui","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1073\/pnas.1604520113","article-title":"Axitinib blocks Wnt\/\u03b2-catenin signaling and directs asymmetric cell division in cancer","volume":"113","author":"Qu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/15384101.2016.1235850","article-title":"Small molecule induces Wnt asymmetry in cancer","volume":"16","author":"Qu","year":"2016","journal-title":"Cell Cycle"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nchembio.2510","article-title":"Small molecule promotes \u03b2-catenin citrullination and inhibits Wnt signaling in cancer","volume":"14","author":"Qu","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"173748","DOI":"10.1016\/j.ejphar.2020.173748","article-title":"A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19","volume":"891","author":"Lokhande","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1328341","DOI":"10.1080\/2162402X.2017.1328341","article-title":"Trial watch: Dendritic cell-based anticancer immunotherapy","volume":"6","author":"Garg","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/sji.12126","article-title":"Activation of peroxisome proliferator-activated receptor gamma leads to upregulation of ESE-3 expression in human monocyte-derived dendritic cells","volume":"79","author":"Sprater","year":"2013","journal-title":"Scand. J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_24","unstructured":"Alexa, A., and Rahnenfuhrer, J. Enrichment Analysis for Gene Ontology, R package version 2.42.0."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41551-018-0250-x","article-title":"Towards superior dendritic-cell vaccines for cancer therapy","volume":"2","author":"Saxena","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-emergence of dendritic cell vaccines for cancer treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Heine, A., Held, S.A.E., Daecke, S.N., Riethausen, K., Kotthoff, P., Flores, C., Kurts, C., and Brossart, P. (2015). The VEGF-receptor inhibitor axitinib impairs dendritic cell phenotype and function. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128897"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nature08356","article-title":"Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling","volume":"461","author":"Huang","year":"2009","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00262-017-2029-4","article-title":"Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-\u03b3 and multiple toll-like receptor agonists","volume":"66","author":"Sarhan","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16334","DOI":"10.1074\/jbc.M112.437962","article-title":"Reduced immunosuppressive properties of Axitinib in comparison with other tyrosine kinase inhibitors","volume":"288","author":"Stehle","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.imbio.2017.10.049","article-title":"Dual requirement for STAT signaling in dendritic cell immunobiology","volume":"223","author":"Donninelli","year":"2018","journal-title":"Immunobiology"},{"key":"ref_34","first-page":"2514","article-title":"Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs","volume":"6","author":"Maenhout","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CMR.0b013e3283538293","article-title":"Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model","volume":"22","author":"Bose","year":"2012","journal-title":"Melanoma Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-016-1836-3","article-title":"Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion","volume":"65","author":"Maenhout","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","article-title":"Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses","volume":"111","author":"Hipp","year":"2008","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: Perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2019","journal-title":"Med. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to Modulate Antitumor Immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/2326-6066.CIR-17-0594","article-title":"TK inhibitor pazopanib primes DCs by downregulation of the \u03b2-catenin pathway","volume":"6","author":"Zizzari","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fphar.2019.00051","article-title":"Drug repurposing: The anthelmintics Niclosamide and Nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways","volume":"10","author":"Miner","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exppara.2007.06.008","article-title":"Neospora caninum: Functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides","volume":"118","author":"Naguleswaran","year":"2008","journal-title":"Exp. Parasitol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/1570163814666170727130003","article-title":"Update on Nitazoxanide: A multifunctional chemotherapeutic agent","volume":"15","author":"Shakya","year":"2018","journal-title":"Curr. Drug Discov. Technol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/8\/949\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:39:39Z","timestamp":1760164779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/8\/949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["biomedicines9080949"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9080949","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2021,8,3]]}}}